The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney Disease

This activity includes patient counseling video vignettes.

Program Description
Type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular disease (CVD) are among the most prevalent conditions in the United States. Often, patients living with T2D are at increased risk for both CVD and CKD. In recent years, increasing trends in diagnosis of these conditions have resulted in the investigation into medications that can improve treatment and management of all 3 of these conditions. New indications in the sodium-glucose cotransporter-2 (SGLT2) inhibitor class in particular have expanded to improve glucose control, CVD outcomes, and safety in patients with CKD. This program will focus on the role of the pharmacist in optimizing use of SGLT2 inhibitors in the treatment and management of diabetes and CVD according to guideline recommendations and highlight their emerging data in CKD. The included patient counseling video vignettes will present opportunities for pharmacists to improve identification of patients with one or more of these overlapping conditions and engage in shared decision-making throughout treatment, management, and monitoring to improve outcomes with SGLT2 inhibitors.

Target Audience: Health System Pharmacist, Retail Pharmacist, Specialty Pharmacist

Type of Activity: Application
Release date: April 1, 2024
Expiration date: April 1, 2025
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the interrelationship of cardiovascular disease (CVD), type 2 diabetes (T2D), and chronic kidney disease in the framework of their effect on diagnosis, management, and prognosis
• Investigate the sodium-glucose cotransporter-2 (SGLT2) inhibitors that have been shown in randomized controlled clinical trials to treat T2D, CVD, and kidney diseases
• Apply the pharmacist’s skill and expertise to counsel patients on the use of SGLT2 inhibitors for optimal outcomes

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-24-059-H01-P. The activity is available for CE credit through April 1, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Darren Mensch, PharmD, BCPS, BCACP has the following relevant financial relationships with commercial interests to disclose:

Stock: Oak Street Health

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Sarah M. Aldrich Renner, PharmD, BCACP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms